MetaCap

Standard BioTools Inc. (LAB)

NASDAQ: LABIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

0.631+0.0173 (+2.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LAB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$249.11M
EPS (TTM)
-$0.09
52-week range
0.39 – 1.72
Day range
0.5729 – 0.65
Volume / Avg
2.81M / 1.16M
Beta
—

52-week range

$0.39$1.72

LAB stock today

Standard BioTools (LAB) closed at $0.631 on Nov 20, up 2.82% (+$0.0173), versus the S&P 500's 3.70% decline. Volume was 2.4x the average at 2.81M shares, a sign of unusually heavy trading. Shares are 63.3% below their 52-week high of $1.72, set on Dec 22, 2025 and 61.8% above the 52-week low of $0.39, near the bottom of the past year's range.

LAB is down 50.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.3%. Standard BioTools has posted a net loss over the last twelve months (EPS of -$0.09), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Standard BioTools

Company profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Dr. Michael Egholm Ph.D.
Headquarters
Boston, MA
Employees
385
IPO year
2011

Financial highlights

Full financials

In fiscal 2025, Standard BioTools generated $85.3 million in revenue, down 6.2% from fiscal 2024, its first annual decline since 2024. Standard BioTools reported a net loss of $74.9 million, compared with a loss of $138.9 million a year earlier. Gross margin was 49.9% (up from 49.3%) and operating margin -129.2%.

Standard BioTools annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$85.33M$91.01M$106.34M$97.95M$130.58M
Growth-6.24%-14.42%+8.57%-24.99%-5.47%
Net income$-74.90M$-138.88M$-74.66M$-190.10M$-59.24M
EPS (diluted)$-0.20$-0.52$-0.94$-2.43$-0.78

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$1.35+113.95%

  • Strong buy 0
  • Buy 0
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.06 vs —

LAB news

All LAB news

Standard BioTools peers

Industrials sector
LAB peer companies
CompanyPrice% ChgMarket capCompare
NAUTNautilus Biotechnology Inc.2.12-2.30%$270.03Mvs LAB
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs LAB
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs LAB
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs LAB
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs LAB
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs LAB
EYPTEyePoint Inc.0.2342-11.36%$26.65Mvs LAB
CIRCCircle8 Group Inc.0.1361-12.25%$15.99Mvs LAB

Indexes, lists and sector

Standard BioTools stock FAQ

What is Standard BioTools's stock price today?

LAB last traded at $0.631 as of Nov 20, 4:00 PM EST, up 2.82% on the day. Prices are delayed at least 15 minutes.

Who is Standard BioTools's CEO?

Dr. Michael Egholm Ph.D. is the chief executive officer of Standard BioTools Inc., which has about 385 employees.

What is the LAB 52-week high?

The 52-week high for LAB is $1.72 and the 52-week low is $0.39. The stock is currently 63.3% below its high.

Compare LAB